Enlivex Therapeutics (NASDAQ:ENLV) Given New $7.00 Price Target at HC Wainwright

Enlivex Therapeutics (NASDAQ:ENLV) had its price objective increased by research analysts at HC Wainwright from $6.00 to $7.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and set a $13.00 target price on shares of Enlivex Therapeutics in a research report on Monday, March 3rd.

Enlivex Therapeutics Stock Up 6.9 %

Shares of ENLV opened at $1.09 on Monday. The stock has a market cap of $23.33 million, a PE ratio of -1.11 and a beta of 1.11. Enlivex Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.59. The business has a 50-day simple moving average of $1.10 and a two-hundred day simple moving average of $1.24.

Institutional Investors Weigh In On Enlivex Therapeutics

A number of institutional investors have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Enlivex Therapeutics during the fourth quarter worth approximately $742,000. Two Sigma Securities LLC purchased a new position in Enlivex Therapeutics during the 4th quarter worth $26,000. Finally, Renaissance Technologies LLC grew its stake in shares of Enlivex Therapeutics by 112.6% in the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after acquiring an additional 84,203 shares in the last quarter. 1.02% of the stock is owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.